Anthem Biosciences IPO Allotment: Anthem Biosciences public offer's allotment likely to be finalised today - Check steps, direct links and more

Investors can check the status of their IPO allotment on July 17 through the website of the registrar, Kfin Technologies Ltd, by entering their PAN or application number. The allotment status will also be available on the websites of BSE and NSE.

If you applied for the Anthem Biosciences IPO, which was open from July 14 to July 16, the wait is almost over. Share allotment is likely to be finalised on July 17, with the listing expected to take place on July 21.

Anthem Biosciences’ IPO was open for subscription from July 14 to July 16, with the company looking to raise Rs 3,395 crore through the offering. The price band was set at Rs 570 per share. JM Financial is managing the issue, while KFin Technologies is serving as the registrar. After the allotment process is completed, the shares are expected to be listed on both stock exchanges on July 21.

Visit the official website of Kfin Technologies, the IPO registrar.

From the dropdown menu, select ‘Anthem Biosciences IPO’.

Choose one of the available identification options: PAN, Application Number, DP ID/Client ID, or Bank Account Number.

Enter the required details in the selected field.

Click on ‘Search’ to view your IPO allotment status.

Go to the NSE IPO application status tracking page.

Click on “Equity and SME IPO Bid Details.”

From the dropdown menu, select “Anthem Biosciences IPO.”

Enter your Application Number and PAN in the required fields.

Click Submit to check your allotment status.

Visit the official BSE IPO allotment status page.

Select “Equity” from the Issue Type dropdown menu.

Choose “Anthem Biosciences IPO” from the list of available IPOs.

Enter your Application Number or PAN in the designated field.

Complete the captcha by checking the box for “I’m not a robot”, then click Search to view your allotment status.

According to data from investorgain.com, the last reported grey market premium (GMP) for Anthem Biosciences IPO stood at Rs 144 as of July 17, 2025, 09:37 AM. Based on the IPO price band of Rs 570, the estimated listing price is projected at Rs 714. This suggests a potential gain of approximately 25.26% per share over the cap price.

Established in 2006, Anthem Biosciences is a Contract Research, Development, and Manufacturing Organisation (CRDMO) that supports pharmaceutical companies in the development and production of medicines. It serves a diverse global clientele—ranging from emerging biotech startups to major pharmaceutical giants—across 44 countries, including the US, Europe, and Japan.

Check Anthem Biosciences IPO allotment status on NSE:

https://www.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp

Check Anthem Biosciences IPO allotment status on BSE:

https://www.bseindia.com/investors/appli_check.aspx

Check Anthem Biosciences IPO allotment status on Kfin Technologies:

https://ipostatus.kfintech.com/

Mutual fund participation in IPO anchor placements remained strong in June, with investments exceeding Rs 2,688 crore across five of the eight IPOs launched during the month. Meanwhile, MFs during the month abstained from both anchor investments and public subscriptions in three issues—Globe Civil Projects, Arisinfra Solutions, and Indogulf Cropsciences. (Read More)

As long as the Nifty 50 remains below 25,250, consolidation may continue, with 25,100–25,000 acting as the support zone. However, if it manages to close strongly above these levels, 25,400 becomes the immediate resistance (23.6% retracement), followed by 25,550, according to experts. (Read More)

Stocks like Tech Mahindra, Angel One, L&T Technology Services, Le Travenues Technology, Maruti Suzuki India, State Bank of India, Godrej Properties, Hindustan Zinc, Zydus Lifesciences, Emcure Pharmaceuticals, JSW Energy, and Smartworks Coworking Spaces will be in focus on July 17. (Read More)

JM Financial has been working as the advisor for the Anthem Biosciences IPO.

The company reported a 30% rise in its operating revenue, which grew to Rs 1,844 crore in the current financial year, up from Rs 1,419 crore in the previous year.

The price band for the IPO was set at Rs 540 to Rs 570 per equity share.

The company aimed to raise Rs 3,395 crore through this public issue. The entire offering is structured as an Offer-for-Sale (OFS), with no fresh equity issuance involved.

Anthem Biosciences is a prominent Indian Contract Research, Development & Manufacturing Organisation (CRDMO). It caters to pharmaceutical and biotechnology companies through a wide range of services in drug development and manufacturing.

Anthem Biosciences shares are expected to be listed on 21 July 2025, on both the BSE and NSE.

The IPO opened for subscription on 14 July and concluded on 16 July 2025.

During the IPO window, the grey market premium (GMP) for Anthem Biosciences shares rose steadily, indicating positive sentiment among unofficial market participants.

Anthem Biosciences' IPO, which closed on 16 July 2025, received strong demand from investors across categories. The offering was subscribed a robust 63.86 times by the end of the bidding period.

Qualified Institutional Buyers (QIBs): Subscribed 182.65 times

Non-Institutional Investors (NIIs): Subscribed 42.35 times

Retail Individual Investors (RIIs): Subscribed 5.64 times

Employee Quota: Subscribed 6.59 times

The share allotment for Anthem Biosciences’ IPO is likely to be finalised today i.e. 17 July 2025. Investors who applied for the issue can check their allotment status through the official websites of BSE and NSE.

Hello and welcome to Moneycontrol. Today, we are tracking the allotment buzz of Anthem Biosciences IPO. Alos on our radar will be the fresh development on Trump vs Powell and new tariff negotiations. Stay with us for latest business news from India and around the world.